In the US, psilocybin and MDMA sit in Schedule I — the government's most restrictive drug category, reserved for substances it says have no accepted medical use and high abuse potential. Moving a drug out of that category requires a lengthy scientific review by two federal agencies. That process hasn't even started for these drugs, so it can't finish by the end of 2026.
Schedule I controls hold. No enforcement infrastructure exists for legal supply chains, and diversion evidence keeps accumulating. Rescheduling requires an HHS/DEA scientific review process that has not been initiated for these substances, making a completed rescheduling in the calendar year effectively impossible.